For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
- Vinblastine (Velban) patient drug information (Chemocare)
- Vinblastine (Velban) patient drug information (UpToDate)
Diseases for which it is used
- Bladder cancer
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Non-small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Diseases for which it was used
- Breast cancer
- Head and neck cancer
- Prostate cancer
- Renal cell carcinoma
- Small cell lung cancer
History of changes in FDA indication
- 11/25/1965: Initial approval
- Uncertain date: Approved for generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system).
- Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated).
- Uncertain date: Approved for histiocytic lymphoma.
- Uncertain date: Approved for mycosis fungoides (advanced stages).
- Uncertain date: Approved for advanced carcinoma of the testis. (Based on Loehrer et al. 1988)
- Uncertain date: Approved for Kaposi's sarcoma.
- Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X).
- Uncertain date: Approved for choriocarcinoma resistant to other chemotherapeutic agents.
- Uncertain date: Approved for carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.
Also known as
- Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
- Brand names: